Related Experiment Videos

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

R Honda1, H Tanaka, H Yasuda

  • 1School of Life Science, Tokyo University of Pharmacy and Life Science, Japan.

FEBS Letters
|February 5, 1998
PubMed

Insights

The tumor suppressor p53 is degraded by the MDM2 oncoprotein, which acts as an E3 ubiquitin ligase. This process involves polyubiquitination and is crucial for regulating p53 levels in cells lacking E6 protein.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • The tumor suppressor p53 plays a critical role in preventing cancer.
  • p53 levels are tightly regulated by the ubiquitin-proteasome system.
  • The MDM2 oncoprotein is known to interact with and regulate p53.

Purpose of the Study:

  • To elucidate the mechanism by which MDM2 regulates p53 degradation.
  • To identify the role of MDM2 as a ubiquitin ligase (E3) in p53 regulation.
  • To investigate the specific molecular interactions involved in p53 ubiquitination.

Main Methods:

  • In vitro ubiquitination assays using purified proteins.
  • Analysis of polyubiquitination of p53 in the presence of E1, UbcH5 (E2), and MDM2.
  • Site-directed mutagenesis to investigate the role of the cysteine residue in MDM2.

Main Results:

  • p53 undergoes polyubiquitination mediated by E1, UbcH5 (E2), and MDM2.
  • MDM2 functions as an E3 ubiquitin ligase for p53.
  • A sulfhydroxy bond links ubiquitin to MDM2, characteristic of E3-ubiquitin binding.
  • The cysteine residue at the carboxyl terminus of MDM2 is essential for its ligase activity.

Conclusions:

  • MDM2 acts as an E3 ubiquitin ligase, targeting p53 for degradation via the ubiquitin-proteasome system.
  • This regulatory mechanism is active in cells lacking the E6 protein, such as those uninfected by human papillomavirus.
  • The findings highlight a key pathway for p53 homeostasis and tumor suppression.

Related Concept Videos